Latest news from NovoCure on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/new-data-finds-tumor-treating-fields-initiates-downstream-anti-tumor-response/?sc=rsin /articles/new-data-finds-tumor-treating-fields-initiates-downstream-anti-tumor-response/?sc=rsin Fri, 25 Feb 2022 12:25:39 EST St. Helier, Jersey - Novocure (NASDAQ: NVCR) announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption activates the immune system and triggers an anti-tumor cell response that may be effectively used together with existing immunotherapy approaches in the treatment of solid tumors, with limited systemic toxicity. NovoCure /articles/novocure-establishes-initial-clinical-centers-of-excellence-for-treatment-of-recurrent-glioblastoma-multiforme-with-tumor-treating-fields-ttfields-therapy/?sc=rsin /articles/novocure-establishes-initial-clinical-centers-of-excellence-for-treatment-of-recurrent-glioblastoma-multiforme-with-tumor-treating-fields-ttfields-therapy/?sc=rsin Fri, 02 Dec 2011 09:00:00 EST Four clinical sites in the U.S. have completed required training and are certified to provide novel therapy to patients using the NovoTTF-100A System(tm); three additional clinical sites planned by year end. NovoCure /articles/professor-zvi-ram-presents-phase-iii-recurrent-glioblastoma-survival-and-quality-of-life-data-from-the-first-pivotal-study-of-the-novottf-100a/?sc=rsin /articles/professor-zvi-ram-presents-phase-iii-recurrent-glioblastoma-survival-and-quality-of-life-data-from-the-first-pivotal-study-of-the-novottf-100a/?sc=rsin Fri, 19 Nov 2010 13:00:00 EST Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual Scientific Meeting. NovoCure /articles/successful-phase-iii-clinical-trial-results-reported-for-novocure-s-novel-medical-device-for-treatment-of-recurrent-glioblastoma/?sc=rsin /articles/successful-phase-iii-clinical-trial-results-reported-for-novocure-s-novel-medical-device-for-treatment-of-recurrent-glioblastoma/?sc=rsin Sat, 05 Jun 2010 09:00:00 EST Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, noninvasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments. NovoCure /articles/novocure-ltd-anounces-the-closing-of-a-financial-round-including-new-investors-pfizer-inc-johnson-johnson-development-corporation-and-index-ventures22/?sc=rsin /articles/novocure-ltd-anounces-the-closing-of-a-financial-round-including-new-investors-pfizer-inc-johnson-johnson-development-corporation-and-index-ventures22/?sc=rsin Mon, 28 Sep 2009 09:00:00 EST Company initiates clinical trial for patients with newly-diagnosed glioblastoma multiforme (GBM). NovoCure